259 related articles for article (PubMed ID: 22435504)
1. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.
Tong JL; Huang ML; Xu XT; Qiao YQ; Ran ZH
J Dig Dis; 2012 Apr; 13(4):200-7. PubMed ID: 22435504
[TBL] [Abstract][Full Text] [Related]
2. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Sandborn WJ; Korzenik J; Lashner B; Leighton JA; Mahadevan U; Marion JF; Safdi M; Sninsky CA; Patel RM; Friedenberg KA; Dunnmon P; Ramsey D; Kane S
Gastroenterology; 2010 Apr; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
[TBL] [Abstract][Full Text] [Related]
3. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Li W; Zhang ZM; Jiang XL
Colorectal Dis; 2016 Jul; 18(7):O214-23. PubMed ID: 27214762
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.
Ford AC; Khan KJ; Sandborn WJ; Hanauer SB; Moayyedi P
Clin Gastroenterol Hepatol; 2012 May; 10(5):513-9. PubMed ID: 22083024
[TBL] [Abstract][Full Text] [Related]
5. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
[TBL] [Abstract][Full Text] [Related]
6. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
Zhu Y; Tang RK; Zhao P; Zhu SS; Li YG; Li JB
Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970
[TBL] [Abstract][Full Text] [Related]
7. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
9. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.
Ford AC; Khan KJ; Sandborn WJ; Kane SV; Moayyedi P
Am J Gastroenterol; 2011 Dec; 106(12):2070-7; quiz 2078. PubMed ID: 21894226
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
11. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000544. PubMed ID: 32856298
[TBL] [Abstract][Full Text] [Related]
12. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
13. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000543. PubMed ID: 32786164
[TBL] [Abstract][Full Text] [Related]
14. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Zheng X; Zhang Z; Wang B; Li J; Qiu C; Zhang Q; Wang X
Medicine (Baltimore); 2019 Apr; 98(14):e15113. PubMed ID: 30946380
[TBL] [Abstract][Full Text] [Related]
16. Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.
Feagan BG; MacDonald JK
Inflamm Bowel Dis; 2012 Sep; 18(9):1785-94. PubMed ID: 22644954
[TBL] [Abstract][Full Text] [Related]
17. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
18. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
[TBL] [Abstract][Full Text] [Related]
19. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
20. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
